Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Momenta Pharmaceuticals Dropped 13.5% Today

By Brian Orelli, PhD – Aug 10, 2020 at 7:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

No news is apparently bad news.

What happened

Without any meaningful revenue, Momenta Pharmaceuticals' (MNTA) second-quarter report was rather uneventful, so it's a little surprising to see shares down 13.5% today without any significant news.But perhaps the lack of news is what's making short-term investors head for the exits.

So what

Momenta recorded $6.6 million in product revenue from sales of Novartis' Glatopa, a generic version of multiple sclerosis treatment Copaxone. That was double the same period a year ago, but nothing to get excited about considering the company lost $57 million during the quarter.

Despite having helped create a couple of drugs, Momenta is essentially still a development-stage biotech, so its cash runway is a lot more important than revenue and earnings. Fortunately, Momenta ended the quarter with over $450 million in the bank, so the drugmaker is in no danger of running out of money in the near term.

Through Friday, shares in Momenta were up 67% year to date thanks to successful proof-of-concept data for nipocalimab as a treatment for generalized myasthenia gravis, a autoimmune neuromuscular disease. It seems likely that some of Monday's decline is simply due to investors hoping there would be additional drug pipeline news and taking profits when no new information materialized.

Man with clenched hands on head looking at computer screens with charts on them.

Image source: Getty Images.

Now what

Long-term investors won't have to wait too much longer for additional clinical trial data for Momenta's pipeline drugs. Later this quarter, Momenta expects to release data for an early stage candidate, M254, being tested for idiopathic thrombocytopenic purpura. Next quarter, investors will get to see the full results from the nipocalimab phase 2 study in generalized myasthenia gravis.

Momenta is still a long way out from getting its next drug on the market, so long-term investors can ignore the day-to-day gyrations in the stock price and focus on the continued development of the company's pipeline, which will ultimately determine Momenta's long-term value.

Brian Orelli, PhD has no position in any of the stocks mentioned. The Motley Fool recommends Momenta Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Momenta Pharmaceuticals, Inc. Stock Quote
Momenta Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.